| Sponsor |
Therapeutic Area |
Target |
Actual |
Met |
Notes |
| Flexion |
Osteoarthritis |
8 |
0 |
| Waiting for HREC application |
| UCB |
Rheumatoid Arthritis |
5 |
0 |
| Waiting for HREC application |
| UCB |
Rheumatoid Arthritis |
5 |
0 |
| Waiting for HREC approval |
| Celgene |
Ankylosing Spondylitis |
5 |
0 |
| Waiting for HREC approval |
| Novartis |
Psoriatic Arthritis |
10 |
8 |
| |
| Investigator Initiated |
Rheumatoid Arthritis |
45 |
0 |
| Waiting for SA site to be approved. |
| Novartis |
Chronic Obstructive Pulmonary Disease |
7 |
0 |
| SIV scheduled 18 May 12 |
| Pfizer |
Smoking Cessation |
12 |
11 |
| |
| Novartis |
Polymyalgia Rheumatica |
3 |
0 |
| Currently waiting for the sponsor to finalise CTA with pharmacy |
| Eli Lilly |
Psoriasis |
6 |
0 |
| Currently on hold waiting for HREC submission |
| UCB |
Systemic Lupus Erythematosus |
5 |
7 |
| |
| Auxilium |
Dupuytren's Contracture |
10 |
10 |
| |
| Novotech |
Gout |
10 |
10 |
| 4 screen failures |
| Merck Sharp & Dohme |
Varicella Zoster Virus Vaccine |
10 |
0 |
| Will commence second 1/4 2012 |
| Auxilium |
Dupuytren's Contracture |
0 |
0 |
| Retreatment of dupytren's contractures from a previous study AUX-CC-860 - no target |
| Novavax |
Influenza Vaccine |
125 |
125 |
| |
| Sanofi Pasteur |
Influenza Vaccine |
100 |
100 |
| |
| Novartis |
Polymyalgia Rheumatica |
5 |
0 |
| Will commence Feb/Mar 2012 |
| Abbott |
Low Back Pain |
10 |
0 |
| Will commence February 2012 |
| Investigator Initiated |
Rheumatoid Arthritis |
180 |
0 |
| 4 sites in Australia to recruit 45 participants each - A/Professor Stephen Hall, Dr. Paul Bird, Dr. Peter Nash & Dr. Maureen Rischmueller |
| Abbott |
Device |
10 |
2 |
| |
| Pfizer |
Smoking Cessation |
20 |
14 |
| |
| Eli Lilly |
Orthopaedics |
6 |
0 |
| Commencing March 2012 |
| Pfizer |
Psoriasis |
8 |
11 |
| |
| UCB |
Systemic Lupus Erythematosus |
5 |
11 |
| |
| Cephalon |
Sciatica |
10 |
0 |
| commence 2012 |
| Pfizer |
Smoking Cessation |
10 |
10 |
| |
| Kendle |
Ross River Virus |
100 |
357 |
| |
| Celgene |
Psoriatic Arthritis |
5 |
12 |
| |
| Bristol-Myers Squibb |
Rheumatoid Arthritis |
5 |
8 |
| Commence 2011 |
| Pfizer |
Psoriasis |
10 |
10 |
| |
| Eli Lilly |
Systemic Lupus Erythematosus |
3 |
0 |
| Commence 2011 |
| Eli Lilly |
Rheumatoid Arthritis |
3 |
1 |
| Commence 2011 |
| AstraZeneca |
Cardiac Endpoint Study |
12 |
1 |
| Advertising campaign not successful
Very high pre-screen failure rate
Decision - stop recruiting by PI |
| Roche |
Rheumatoid Arthritis |
5 |
7 |
| 1 screen failure
|
| Abbott |
Peripheral Spondyloarthritis |
5 |
10 |
| |
| Pfizer |
Rheumatoid Arthritis |
5 |
7 |
| |
| Janssen Cilag |
Psoriatic Arthritis |
4 |
9 |
| 3 screen failures |
| Pfizer |
Rheumatoid Arthritis |
6 |
10 |
| Top recruiting site in Australia.
A3921064 |
| Pfizer |
Rheumatoid Arthritis |
8 |
20 |
| Top recruiting site in Australia
A3921046 |
| Pfizer |
Rheumatoid Arthritis |
8 |
10 |
| A3921044 |
| Roche |
Rheumatoid Arthritis |
5 |
18 |
| |
| Mesoblast Inc |
Orthopaedics |
24 |
13 |
| Stem Cell Research in ACL injury |
| GlaxoSmithKline |
Heart Disease |
20 |
18 |
| Recruitment closed early - canceled bookings |
| Abbott |
Rheumatoid Arthritis |
8 |
9 |
| |
| Roche |
Rheumatoid Arthritis |
8 |
9 |
| |
| Roche |
Rheumatoid Arthritis |
8 |
9 |
| |
| Bristol-Myers Squibb |
Rheumatoid Arthritis |
4 |
6 |
| |
| Auxilium |
Dupuytren's Contracture |
15 |
16 |
| |
